Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
|Videos|November 4, 2022
RSV, influenza, and COVID-19: Gearing up for the threat of a 'triple epidemic'
Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the rising threat of a "triple epidemic" consisting of influenza, COVID-19, and RSV in children.
Advertisement
Contemporary Pediatrics® Editor-in-Chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the recent surge in pediatric RSV hospitalizations and the rising threat of the "triple epidemic" consisting of influenza, COVID-1, and RSV in children.
Advertisement
Related to this article
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
An updated AAP policy statement renews the call to ban raw milk sales, citing pathogen risks to children and pregnant people and an emerging H5N1 concern.
At AAP 2026, Rana Hamdy, MD, discussed when to test children for group A strep, antibiotic selection, and strategies to improve prescribing.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Youth-onset type 2 diabetes may progress faster, signs easy to miss
2
FDA sets new PDUFA date for Anaphylm for type I allergic reactions
3
When one young athlete’s cardiac arrest revealed a family at risk
4
FDA grants Cinainu Breakthrough Therapy status for pediatric AA
5